Michael Barbella, Managing Editor09.22.22
A Cook County, Ill., jury has awarded $363 million to a breast cancer survivor living less than half a mile from a medical device sterilization plant for more than three decades.
The trial was the first of many expected against Sterigenics, which operated a sterilization facility in Willowbrook, Ill., until 2019. There are more than 760 lawsuits pending against Sterigenics in Cook County Circuit Court.
Sterigenics vowed to appeal the jury's decision.
“We do not believe the jury verdict in this matter reflects the evidence presented in court. Sterigenics is evaluating the verdict and plans to challenge this decision through all appropriate process, including appeals," a company spokesman said in a formal statement to ODT. "We will continue to vigorously defend against allegations about our ethylene oxide operations and emissions. We remain committed to our mission of Safeguarding Global Health. As we have consistently done throughout our history, we will continue to operate in compliance with applicable rules and regulations to ensure the safety of our employees, the communities in which we operate and patients around the world.”
Federal officials began investigating Sterigenics in 2018 after the community surrounding the Willowbrook plant was identified on a national map of health hazards from breathing toxic chemicals. Data reported by the company to the U.S. Environmental Protection Agency showed the Willowbrook census tract was in the 99.9th percentile for cancer risk in the country. The EPA study pointed to Sterigenics’ EtO emissions as a potential cause, prompting public outrage and hundreds of lawsuits against the Willowbrook plant.
The first plaintiff to take the company to trial was Sue Kamuda, now 70, who was diagnosed with breast cancer in 2007 and underwent surgery and several rounds of both chemotherapy and radiation to treat her illness. She is currently in remission. Kamuda and her husband moved to Willowbrook in 1985, less than a year after Sterigenics began operations in the community. During the trial, Kamuda called the day she moved into the home “the happiest day of her life.”
All three of Kamuda’s children attended school within a mile of the plant. Her son, Brian Kamuda, was diagnosed with non-hodgkin’s lymphoma in 2021 and has filed a lawsuit against Sterigenics.
During the trial, which opened on Aug. 18, Kamuda’s attorneys argued Sterigenics (formerly Micro-Biotrol Inc.) knew the risks of using ethylene oxide (EtO) to sterilize medical equipment yet continued to utilize “excessive and unnecessary” amounts of the colorless, odorless carcinogen for decades without warning the community. During their opening statements, the plaintiff’s attorneys showed a video demonstrating how Sterigenics employees would seal products in a room before the gas was released. The gas would then penetrate through boxes, wrapping and other packaging to kill every living microorganism on the products. Before employees could re-enter the sterilization chamber, the poisonous gas would be released from the building and into the community through a vacuum pump. During this process, employees were strictly instructed to wear biohazard gear to protect themselves from the carcinogen.
Kamuda's attorneys also presented the jury with company emails and other documents to demonstrate that Sterigenics executives and former parent company Griffith Foods knew since the early 1980s that EtO exposure posed significant health risks to humans, but the company pushed back on studies and regulatory efforts to maintain profitability.
“They (Sterigenics) did not treat EtO like a carcinogen, they treated it like an ATM,” attorney Patrick A. Salvi II said during trial. “They consistently underplayed their EtO use in reports to regulators so they could fly under the radar and continue making money off this toxic operation. They were paying their executives hundreds of millions of dollars, all while Sue and her neighbors were unknowingly being exposed to this insidious chemical.”
Kamuda has no family history that would make her genetically predisposed to cancer and prior to her diagnosis. She testified that prior to her diagnosis, she was an avid runner who enjoyed running 5Ks with her family. While Kamuda is still active in other ways, she has not resumed running since her illness.
During the trial, a former Sterigenics CEO testified that he knew EtO was dangerous when he stepped into the leadership position in 2011, but never issued directives to tighten up inconsistent emissions controls across Sterigenics’ facilities. He also said the company could have reduced emissions back in the early 2000s. When he left his position as CEO in 2016, the company’s profits had increased from about $94 million to $225 million, which was attributed to the acquisition of other companies and increased sterilization.
It was further alleged Sterigenics and parent company Sotera began funneling $1.3 billion of its assets to investors beginning in 2016, when the unfavorable EPA reports were finalized regarding the potency of ethylene oxide.
Defense attorneys focused their case on the “commonality” of breast cancer and claimed the company was on the cutting edge of technology. They also cited other environmental factors, such as the nearby Kingery Highway, as a potential cause of Kamuda’s cancer. Counsel for Griffith argued they did not participate in the emissions first-hand and they sold Micro-Biotrol by 1999, releasing them of any liability.
“Defense’s argument of the commonality of this illness essentially says that no woman can come to court alleging a chemical exposure caused their cancer. Despite the commonality, you cannot deny that EtO has been linked to breast cancer,” Salvi II said in rebuttal, citing multiple scientific studies on the dangers of EtO.
Closing arguments were delivered on Sept. 15 before the Honorable Marguerite Quinn. On Sept. 19, the jury returned their verdict, awarding Kamuda $363 million—including $38 million in compensatory damages and $325 million in punitive damages. The verdict is now the highest jury verdict on record for an individual plaintiff in Illinois.
“We are immensely thankful to the jury for sitting through such a lengthy trial and for providing Sue with the justice she deserves. But this verdict is about more than Sue, it’s about holding these companies accountable. There are many more cases to be tried and we hope Sue’s case sets a precedent that Sterigenics cannot distort science with money, and they should be held liable for gambling with people’s lives,” attorney Lance D. Northcutt.
Sterigenics closed its Willowbrook facility in the fall of 2019. Since the plant’s closure, the state has enacted strict new EtO emission limits and Sterigenics has ceased seeking operations in Illinois. Sterigenics still operates several plants throughout the country.
Kamuda was represented at trial by Salvi II, Northcutt, and Jennifer M. Cascio of the Illinois law firm Salvi, Schostok & Pritchard P.C.; Shawn Collins and Margaret Galka of The Collins Law Firm; and Scott A. Entin, Roisin Duffy-Gideon, and Deanna N. Pihos of Miner, Barnhill & Galland P.C.
The trial was the first of many expected against Sterigenics, which operated a sterilization facility in Willowbrook, Ill., until 2019. There are more than 760 lawsuits pending against Sterigenics in Cook County Circuit Court.
Sterigenics vowed to appeal the jury's decision.
“We do not believe the jury verdict in this matter reflects the evidence presented in court. Sterigenics is evaluating the verdict and plans to challenge this decision through all appropriate process, including appeals," a company spokesman said in a formal statement to ODT. "We will continue to vigorously defend against allegations about our ethylene oxide operations and emissions. We remain committed to our mission of Safeguarding Global Health. As we have consistently done throughout our history, we will continue to operate in compliance with applicable rules and regulations to ensure the safety of our employees, the communities in which we operate and patients around the world.”
Federal officials began investigating Sterigenics in 2018 after the community surrounding the Willowbrook plant was identified on a national map of health hazards from breathing toxic chemicals. Data reported by the company to the U.S. Environmental Protection Agency showed the Willowbrook census tract was in the 99.9th percentile for cancer risk in the country. The EPA study pointed to Sterigenics’ EtO emissions as a potential cause, prompting public outrage and hundreds of lawsuits against the Willowbrook plant.
The first plaintiff to take the company to trial was Sue Kamuda, now 70, who was diagnosed with breast cancer in 2007 and underwent surgery and several rounds of both chemotherapy and radiation to treat her illness. She is currently in remission. Kamuda and her husband moved to Willowbrook in 1985, less than a year after Sterigenics began operations in the community. During the trial, Kamuda called the day she moved into the home “the happiest day of her life.”
All three of Kamuda’s children attended school within a mile of the plant. Her son, Brian Kamuda, was diagnosed with non-hodgkin’s lymphoma in 2021 and has filed a lawsuit against Sterigenics.
During the trial, which opened on Aug. 18, Kamuda’s attorneys argued Sterigenics (formerly Micro-Biotrol Inc.) knew the risks of using ethylene oxide (EtO) to sterilize medical equipment yet continued to utilize “excessive and unnecessary” amounts of the colorless, odorless carcinogen for decades without warning the community. During their opening statements, the plaintiff’s attorneys showed a video demonstrating how Sterigenics employees would seal products in a room before the gas was released. The gas would then penetrate through boxes, wrapping and other packaging to kill every living microorganism on the products. Before employees could re-enter the sterilization chamber, the poisonous gas would be released from the building and into the community through a vacuum pump. During this process, employees were strictly instructed to wear biohazard gear to protect themselves from the carcinogen.
Kamuda's attorneys also presented the jury with company emails and other documents to demonstrate that Sterigenics executives and former parent company Griffith Foods knew since the early 1980s that EtO exposure posed significant health risks to humans, but the company pushed back on studies and regulatory efforts to maintain profitability.
“They (Sterigenics) did not treat EtO like a carcinogen, they treated it like an ATM,” attorney Patrick A. Salvi II said during trial. “They consistently underplayed their EtO use in reports to regulators so they could fly under the radar and continue making money off this toxic operation. They were paying their executives hundreds of millions of dollars, all while Sue and her neighbors were unknowingly being exposed to this insidious chemical.”
Kamuda has no family history that would make her genetically predisposed to cancer and prior to her diagnosis. She testified that prior to her diagnosis, she was an avid runner who enjoyed running 5Ks with her family. While Kamuda is still active in other ways, she has not resumed running since her illness.
During the trial, a former Sterigenics CEO testified that he knew EtO was dangerous when he stepped into the leadership position in 2011, but never issued directives to tighten up inconsistent emissions controls across Sterigenics’ facilities. He also said the company could have reduced emissions back in the early 2000s. When he left his position as CEO in 2016, the company’s profits had increased from about $94 million to $225 million, which was attributed to the acquisition of other companies and increased sterilization.
It was further alleged Sterigenics and parent company Sotera began funneling $1.3 billion of its assets to investors beginning in 2016, when the unfavorable EPA reports were finalized regarding the potency of ethylene oxide.
Defense attorneys focused their case on the “commonality” of breast cancer and claimed the company was on the cutting edge of technology. They also cited other environmental factors, such as the nearby Kingery Highway, as a potential cause of Kamuda’s cancer. Counsel for Griffith argued they did not participate in the emissions first-hand and they sold Micro-Biotrol by 1999, releasing them of any liability.
“Defense’s argument of the commonality of this illness essentially says that no woman can come to court alleging a chemical exposure caused their cancer. Despite the commonality, you cannot deny that EtO has been linked to breast cancer,” Salvi II said in rebuttal, citing multiple scientific studies on the dangers of EtO.
Closing arguments were delivered on Sept. 15 before the Honorable Marguerite Quinn. On Sept. 19, the jury returned their verdict, awarding Kamuda $363 million—including $38 million in compensatory damages and $325 million in punitive damages. The verdict is now the highest jury verdict on record for an individual plaintiff in Illinois.
“We are immensely thankful to the jury for sitting through such a lengthy trial and for providing Sue with the justice she deserves. But this verdict is about more than Sue, it’s about holding these companies accountable. There are many more cases to be tried and we hope Sue’s case sets a precedent that Sterigenics cannot distort science with money, and they should be held liable for gambling with people’s lives,” attorney Lance D. Northcutt.
Sterigenics closed its Willowbrook facility in the fall of 2019. Since the plant’s closure, the state has enacted strict new EtO emission limits and Sterigenics has ceased seeking operations in Illinois. Sterigenics still operates several plants throughout the country.
Kamuda was represented at trial by Salvi II, Northcutt, and Jennifer M. Cascio of the Illinois law firm Salvi, Schostok & Pritchard P.C.; Shawn Collins and Margaret Galka of The Collins Law Firm; and Scott A. Entin, Roisin Duffy-Gideon, and Deanna N. Pihos of Miner, Barnhill & Galland P.C.
